Barclays on Global Biopharma Stocks: American Diabetes Association 2012: Highlights From GSK, LLY, SNY, NVO & JNJ

Barclays on Global Biopharma stocks: American Diabetes Association (ADA) 2012

Analyst, C. Anthony Butler, said, "...the weekend highlighted potential new competition to incumbents in the diabetes space, particularly for insulins (Lilly's LY2605541), GLP-1s (Sanofi's lixisenatide, GlaxoSmithKline's albiglutide) and SGLT-2s (JNJ canagliflozin foremost). We reiterate our Overweight rating on Sanofi (NYSE: SNY) where expectations are low, although there could be significant volatility around release of the Lantus ORIGIN data, due imminently. We reiterate our Underweight rating on Novo Nordisk (NYSE: NVO), where expectations seem high. GlaxoSmithKline's (NYSE: GSK)(2-EW) abiglutide and Johnson & Johnson's (NYSE: JNJ)(1-OW) canagliflozin seem unlikely to materially move the needle for these big companies. Lilly's (NYSE: LLY) (2-EW) new insulin seems promising, although that stock seems driven more by expectations around new Alzheimer's agents."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Senate Committee Investigates Ozempic and Wegovy Costs - NYT
• Pacific Premier Bancorp (PPBI) PT Lowered to $27 at Keefe, Bruyette & Woods
• Northland Starts Bitfarms Ltd. (BITF) at Outperform